GigaGen is working on a recombinant polyclonal antibody, recombinant anti-coronavirus 19 hyperimmune gammaglobulin (rCIG), as a Covid-19 treatment.
The therapy reproduces whole antibody repertoires of recovered patients, including antibodies that block further replication of the novel coronavirus.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
GigaGen will formulate the antibody for intravenous administration to deliver passive immunity.
